Study disclosure:
The authors declare that their CCSVI studies were funded with internal resources of the Buffalo
Neuroimaging Analysis Center, Jacobs MS Comprehensive and Research Center, University at Buffalo. In
addition, they received support from the Direct MS Foundation, Kaleida-Health, Volcano, ev3, Codman,
the Jacquemin Foundation, and from minor donors.
Potential Conflict of Interest:
Kresimir Dolic, Yuval Karmon and Karen Marr have nothing to disclose.
Dr. Siddiqui has received research grants from the National Institutes of Health (co-investigator: NINDS
1R01NS064592-01A1, Hemodynamic induction of pathologic remodeling leading to intracranial
aneurysms) and the University at Buffalo (Research Development Award); holds financial interests in
Hotspur, Intratech Medical, StimSox, and Valor Medical; serves as a consultant to Codman & Shurtleff,
Inc., Concentric Medical, ev3/Covidien Vascular Therapies, GuidePoint Global Consulting, Penumbra
and Stryker Neurovascular; belongs to the speakers’ bureaus of Codman & Shurtleff, Inc. and Genentech;
serves on National Steering Committee for Penumbra, Inc. 3D Separator Trial; serves on an advisory
board for Codman & Shurtleff; and has received honoraria from American Association of Neurological
Surgeons’ courses, Genentech, Neocure Group LLC, Annual Peripheral Angioplasty and All That Jazz
Course and from Abbott Vascular and Codman & Shurtleff, Inc. for training other neurointerventionists in
carotid stenting and for training physicians in endovascular stenting for aneurysms. Dr. Siddiqui receives
no consulting salary arrangements. All consulting is per project and/or per hour.
Dr. Zivadinov received financial support for research activities from Biogen Idec, Teva Pharmaceutical
and Teva Neuroscience, EMD Serono, Genzyme-Sanofi, Novartis, Greatbatch, Bracco and Questcor. He
also received personal compensation from Teva Pharmaceutical, Biogen Idec, Novartis, Genzyme-Sanofi,
EMD Serono, Bayer, Novartis and General Electric for speaking and consultant services.